Floatz logo

Tagraxofusp-Erzs

CD4+/CD56+ Hematodermic Neoplasm

M.D. Anderson Cancer CenterPhase 2Active
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
21/ 100
Competitive Position
89/ 100

Competitive context

34 Active assets in the CD4+/CD56+ Hematodermic Neoplasm cohort.

Asset / SponsorPhaseRating
Tagraxofusp
French Innovative Leukemia Organisation
Phase 2BB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 2BB
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
St. Jude Children's Research Hospital
Phase 2B

View all 47 →

Same molecule, other indications

Tagraxofusp-Erzs is also rated in:

lymphoblastic lymphomaDormant
C
Indicative ·
33 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
C
Indicative ·
33 / 100
View asset →
T-cell acute lymphoblastic leukemiaDormant
C
Indicative ·
33 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →